Medisights deploys AI agents to accelerate Multiple Myeloma research
Medisights has launched a new AI-driven methodology capable of capturing real-time market intelligence within the complex landscape of Multiple Myeloma. By deploying specialized AI agents to conduct hour-long clinical conversations with oncologists, the firm bypasses the months-long delays typical of traditional primary market research in life sciences.
The study utilized purpose-built AI moderators to engage specialists in deep, adaptive discussions regarding CAR-T therapies. Unlike traditional qualitative research, which often struggles to secure lengthy physician interviews, these dynamic agents maintained natural interactions lasting 45 to 60 minutes. This approach successfully mapped referral pathways and identified specific barriers to treatment adoption, such as insurance authorization hurdles and confusion among community oncologists regarding viral-vector versus ex vivo cell engineering.
Frank Seo, CEO of Medisights, noted that the platform allows life sciences companies to view regional reference patterns as they emerge. By aligning their agents with curated clinical taxonomies, the company claims to provide a verifiable source of truth for commercial and medical affairs teams. These insights, categorized as Digital Doctor Twins, aim to replace static market reports with a continuous data stream, allowing firms to test messaging and address unmet clinical needs with unprecedented speed.
Comments (0)
No comments yet. Be the first!